0.00%
Today
Loading 1D prices…
Company profile
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD); and with ELEO, Inc. to develop oral small-molecule inhibitors targeting the PCSK9 pathway for the treatment of hyperlipidemia and cardiovascular diseases. The company was incorporated in 1999 and is headquartered in Rehovot, Israel.
Sector
Health Care
Industry
Agricultural Chemicals
Exchange
Nasdaq
Display currency
USD
Location
Rehovot, Israel, United States
Employees
38
Fiscal year end
1231
CIK
1574565
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| SNESSenesTech Inc. Common Stock | $4.6M | $2.2M | -287.39% | -$1.95 | -3.69% | Buy |
| FRTTFort Technology Inc. Common Shares | $14.3M | $10.8M | -53.75% | -$1.38 | -2.06% | Unrated |
| BIOXBioceres Crop Solutions Corp. Ordinary Shares | $26.7M | $333.3M | -16.62% | -$0.8291 | -0.95% | Hold |
| AVDAmerican Vanguard Corporation Common Stock ($0.10 Par Value) | $66.7M | $515.1M | -9.68% | -$1.75 | +1.35% | Unrated |
| CBUSCibus Inc. Class A Common Stock | $120M | $3.6M | -3492.31% | -$2.78 | +0.00% | Hold |